Progestin effects in endometriosis treatment: new research on mechanisms

Alfred O. Mueck, Mueck AO
Hormone molecular biology and clinical investigation · 2010 · vol. 3(3) , pp. 469–472 · doi:10.1515/hmbci.2010.061 · PMID:25961221 · W2335538899
Review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Dienogest shows strong antiproliferative, anti-inflammatory, and antiangiogenic effects in experimental endometriosis while only modestly suppressing estradiol production, making it effective and well-tolerated for long-term therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

New research on mechanisms of progestin effects in endometriosis treatment has been performed with dienogest (DNG), which has recently been launched in this regard. It is effective in the same low dosage of 2 mg/day, similar to the use of contraception and hormone therapy, whereas other progestogens (with the exception of dydrogesterone) must be given in much higher dosages to treat typical symptoms of endometriosis. This short review summarizes experimental studies on DNG. They demonstrate strong antiproliferative effects in endometrial and endometriotic cells or experimental endometriosis, as well as anti-inflammatory and antiangiogenic actions. By direct action on the ovarian folliculogenesis DNG lead to only modest suppression of estradiol production in contrast to the high-dosed progestogens or to gonadotropin releasing hormone (GnRH) agonists. These effects add to the well-known tolerability because DNG is very neutral regarding cardiovascular, metabolic or central action which also makes it suitable for long-term therapy.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:15:29.615373+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK